Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 8/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237393 | 0.85 | HPGD (0.50) | HPGDPTPN1NR4A2MAOBALDH1A1 | |
| SCHEMBL954546 | 0.85 | NR4A2 (0.49) | HPGDPTPN1NR4A2MAOBALDH1A1 | |
| SCHEMBL960147 | 0.85 | NR4A2 (0.54) | HPGDPTPN1NR4A2MAOBNPC1 | |
| SCHEMBL2089649 | 0.84 | HPGD (0.49) | HPGDPTPN1NR4A2MAOBALDH1A1 | |
| SCHEMBL2088041 | 0.84 | HPGD (0.49) | HPGDPTPN1NR4A2MAOBALDH1A1 | |
| SCHEMBL2088037 | 0.84 | HPGD (0.49) | HPGDPTPN1NR4A2MAOBALDH1A1 | |
| Potassium SCHEMBL2089657 | 0.84 | HPGD (0.49) | HPGDPTPN1NR4A2MAOBALDH1A1 | |
| SCHEMBL2088558 | 0.83 | HPGD (0.49) | HPGDPTPN1NR4A2MAOBALDH1A1 | |
| SCHEMBL955931 | 0.80 | HPGD (0.46) | HPGDPTPN1NR4A2MAOB | |
| SCHEMBL4265996 | 0.80 | HPGD (0.67) | HPGDNR4A2ALDH1A1CYP2C19NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947735-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-05-24 | — | — | US | claimed |
| CN-101374415-A | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORP (US) | 2009-02-25 | — | — | CN | claimed |
| US-20080306150-A1 | Compounds for the Treatment of Metabolic Disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-12-11 | — | — | US | claimed |
| EP-1976378-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2008-10-08 | — | — | EP | claimed |
| WO-2007087506-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-08-02 | — | — | WO | claimed |
| US-7947735-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-05-24 | — | — | US | disclosed |
| CN-101374415-A | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORP (US) | 2009-02-25 | — | — | CN | disclosed |
| US-20080306150-A1 | Compounds for the Treatment of Metabolic Disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1976378-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007087506-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306150-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FABP1, CPT1B | HPGD 3215/4885PTPN1 1401/4885NR4A2 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.